Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2022 | $4.00 | Buy | Ladenburg Thalmann |
| 1/20/2022 | $1.00 → $3.00 | Market Perform → Outperform | SVB Leerink |
| 11/8/2021 | Buy → Neutral | HC Wainwright & Co. | |
| 11/5/2021 | Outperform → Market Perform | William Blair |
DEFM14A - Calithera Biosciences, Inc. (0001496671) (Filer)
PREM14A - Calithera Biosciences, Inc. (0001496671) (Filer)
DEFA14A - Calithera Biosciences, Inc. (0001496671) (Filer)
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. "Earlier in the fourth quarter, we were very pleased to announce that we received FDA Fast Track designation for sapanisertib. This designation facilitates more frequent communication with the Agency, as well as a number of other benefits that could support our efforts to bring sapanisertib to patients in this area of high unmet need more quickly," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "Today we a
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants who wish to join the conference call by telephone can use this link to register and receive the dial-in numbers and unique PIN to access the call. The conference call registration and live audio webcast c
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022. "We continue to deliver on our commitment to efficiently advance our clinical programs, successfully initiating two new clinical trials and sharing program updates at two important medical conferences," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "We look forward to sharing data from the ongoing mivavotinib and sapanisertib phase 2 trials by the first quarter of 2023, as well as providing an update on the p
Ladenburg Thalmann initiated coverage of Calithera Biosciences with a rating of Buy and set a new price target of $4.00
SVB Leerink upgraded Calithera Biosciences from Market Perform to Outperform and set a new price target of $3.00 from $1.00 previously
HC Wainwright & Co. downgraded Calithera Biosciences from Buy to Neutral
SC 13D/A - Calithera Biosciences, Inc. (0001496671) (Subject)
SC 13G/A - Calithera Biosciences, Inc. (0001496671) (Subject)
SC 13G/A - Calithera Biosciences, Inc. (0001496671) (Subject)
SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 50,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on December 31, 2020. One-fourth of the option vests in December 2021, and the balance of the option vests in a series of thirty-six successive equ
4 - Calithera Biosciences, Inc. (0001496671) (Issuer)
4 - Calithera Biosciences, Inc. (0001496671) (Issuer)
4 - Calithera Biosciences, Inc. (0001496671) (Issuer)
SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: "CALA"). Calithera Biosciences, Inc. (the "Company") announced that it was unable to achieve a quorum of stockholders at its special meeting of stockholders scheduled to be held on June 29, 2023 (the "Special Meeting"), for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution. In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations. After consulting with its proxy solicitation advisors, the Company concluded that further attempts to solicit proxies for the Special Meeting would in all likelihoo
SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC:CALA) (the "Company") announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the "Special Meeting"), for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution (the "Plan of Dissolution"). In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations. The Company continues to expect that its existing capital resources together with the net proceeds from the sale of its assets will enable it to meet its remaining liabilities and obligations with sufficient reser
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company's operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter. "The Board of Directors and management devoted substantial t
Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This security traded at a volume of 323.6K shares come close, making up 21.6% of its average volume over the last 100 days. The company's market cap stands at $6.1 million. Lannett (NYSE:LCI) shares rose 15.74% to $0.62. The market value of their outstanding shares is at $26.2 million. As per the press release, Q2 earnings came out today. Align Tech (NASDAQ:ALGN) shares rose 15.03% to $325.0. At the close, Align Tech's trading volume reached 121.5K shares. This is 11.8% of its average volume over the last 100 days. The company's market cap stands at $25.3 billion
Gainers Bright Green (NASDAQ:BGXX) shares increased by 251.2% to $1.83 during Wednesday's regular session. The current volume of 81.8 million shares is 25935.4% of Bright Green's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $310.7 million. Erytech Pharma (NASDAQ:ERYP) stock increased by 47.76% to $1.33. Trading volume for Erytech Pharma's stock is 281.1K as of 12:30 EST. This is 628.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $41.2 million. Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 32.93% to $2.22. Quoin Pharmaceuticals's stock is trading at a
Gainers Nymox Pharmaceutical (NASDAQ:NYMX) shares rose 21.8% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $45.2 million. Brainstorm Cell (NASDAQ:BCLI) stock rose 10.83% to $1.93. The company's market cap stands at $70.6 million. OKYO Pharma (NASDAQ:OKYO) stock moved upwards by 6.46% to $2.8. The company's market cap stands at $60.9 million. Creative Medical Tech (NASDAQ:CELZ) stock rose 6.28% to $0.57. The market value of their outstanding shares is at $8.0 million. Athenex (NASDAQ:ATNX) stock rose 5.44% to $0.19. The company's market cap stands at $29.8 million. Virax Biolabs Group (NASDAQ:VRAX) stock moved upwards by 5.28% to $0.78.